Research and Clinical Trials

Title  
COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Brief Description  
To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone. The primary goal in this trial is to prevent relapse. AALL1231 will test two major strategies to meet this goal: (1) to modify the existing chemotherapy platform to mirror the most efficacious backbone that has been tested in Phase 3 trials; and, (2) to randomize patients to receive/not receive a novel agent (bortezomib), with strong b
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Leukemia, not otherwise specified
Status  
OPEN
Start Date  
05/18/2015
IRB Number  
00010588
Principal Investigator  
Kaplan, Joel Adam
Contact Name  
Sceria Jenkins

For More Information, Contact  Sceria  , Jenkins
Phone:  980-442-2323 Fax:    
Email:  sceria.jenkins@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close